Clinical trial
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
NCT00095173 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00095173 |
|---|---|
| Title | BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis |
| Official title | A Phase III, Multi-Center, Multi-National, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents With Active Polyarticular Juvenile Rheumatoid Arthritis (JRA) |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Juvenile Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Abatacept, Placebo |
| Enrollment | 214 |
| Start date | Dec 1, 2003 |
| Primary completion | Jun 1, 2006 |
| Completion | Nov 1, 2011 |
| First posted | Nov 2, 2004 |
| Last update posted | Jan 18, 2017 |
| Countries | Austria, Brazil, France, Germany, Italy, Mexico, Peru, Portugal, Spain, Switzerland, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: